Source:http://linkedlifedata.com/resource/pubmed/id/16412592
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2006-5-8
|
pubmed:abstractText |
Rutaecarpine is a major quinazolinocarboline alkaloid isolated from Evodia rutaecarpa. It was reported to possess a wide spectrum of pharmacological activities, such as vasodilation, antithrombosis, and anti-inflammation. In the present study, adverse effects of rutaecarpine on immune functions were determined in female BALB/c mice. Rutaecarpine had no effects on hepatotoxicity parameters in mice, as measured by serum activities of aminotransferases. Meanwhile, rutaecarpine significantly decreased the number of antibody-forming cells and caused weight decrease in spleen in a dose-dependent manner, when mice were administered with rutaecarpine at 10mg/kg, 20mg/kg, 40 mg/kg or 80 cmg/kg once intravenously. In addition, rutaecarpine administered mice exhibited reduced splenic cellularity, decreased numbers of total T cells, CD4(+) cells, CD8(+) cells, and B cells in spleen. IL-2, interferon-gamma and IL-10 mRNA expressions were suppressed significantly by rutaecarpine treatment. The number of CD4(+)IL-2(+) cells was reduced significantly following administration of mice with rutaecarpine. Furthermore, rutaecarpine caused the cell cycle arrest in G(0)+G(1) phase in a dose-dependent manner. Rutaecarpine caused significant inductions of hepatic cytochrome P450 (CYP) 1A, 2B, and 2E1 activities dose-dependently. In the splenic lymphocyte proliferation assay, rutaecarpine inhibited proliferation by LPS and Con A ex vivo, whereas it had no effects on in vitro proliferation. These results suggested that a single bolus intravenous injection of rutaecarpine from 20mg/kg might cause immunosuppressive effects, and that rutaecarpine-induced immunosuppression might be mediated, at least in part, through the inhibition of cytokine production and cell cycle arrest in G(0)+G(1) phase, and caused possibly by mechanisms associated with metabolic activation.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Alkaloids,
http://linkedlifedata.com/resource/pubmed/chemical/Indole Alkaloids,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Vasodilator Agents,
http://linkedlifedata.com/resource/pubmed/chemical/rutecarpine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0378-4274
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
164
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
155-66
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16412592-Alkaloids,
pubmed-meshheading:16412592-Animals,
pubmed-meshheading:16412592-Antibody Formation,
pubmed-meshheading:16412592-Body Weight,
pubmed-meshheading:16412592-Cell Cycle,
pubmed-meshheading:16412592-Dose-Response Relationship, Drug,
pubmed-meshheading:16412592-Female,
pubmed-meshheading:16412592-Immunosuppression,
pubmed-meshheading:16412592-Indole Alkaloids,
pubmed-meshheading:16412592-Interleukin-2,
pubmed-meshheading:16412592-Mice,
pubmed-meshheading:16412592-Mice, Inbred BALB C,
pubmed-meshheading:16412592-Organ Size,
pubmed-meshheading:16412592-Quinazolines,
pubmed-meshheading:16412592-Spleen,
pubmed-meshheading:16412592-Vasodilator Agents
|
pubmed:year |
2006
|
pubmed:articleTitle |
Immunosuppressive effects of rutaecarpine in female BALB/c mice.
|
pubmed:affiliation |
College of Pharmacy, Yeungnam University, 214-1, Dae-dong, Gyeongsan 712-749, South Korea. taecheon@yumail.ac.kr
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|